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Abstract: Proteases play important roles in a variety of disease processes. Understanding their biological functions un-
derpins the efforts of drug discovery. We have developed a bioluminescent protease assay using a circularly permuted 
form of firefly luciferase, wherein the native enzyme termini were joined by a peptide containing a protease site of inter-
est. Protease cleavage of these mutant luciferases greatly activates the enzyme, typically over 100 fold. The mutant lu-
ciferase substrates are easily generated by molecular cloning and cell-free translation reactions and thus the protease sub-
strates do not need to be chemically synthesized or purchased. The assay has broad applicability using a variety of prote-
ases and their cognate sites and can sensitively detect protease activity. In this report we further demonstrate its utility for 
the evaluation of protease recognition sequence specificity and subsequent establishment of an optimized assay for the 
identification and characterization of protease inhibitors using high throughput screening. 
INTRODUCTION 
  Proteases are a diverse group of enzymes which hydro-
lyze peptide bonds. They are essential for many physiologi-
cal processes including cell proliferation, cell differentiation, 
tissue remodeling, immune response, complement system, 
neuronal outgrowth, angiogenesis, blood coagulation, and 
apoptosis [1]. Accordingly, dysregulation of proteases have 
been implicated in numerous disease states such as cancer, 
osteoporosis, inflammatory disease, neurodegenerative dis-
ease, cardiovascular disease, type 2 diabetes, and acute in-
jury [2]. Modulators to protease activities, either small mole-
cules or antibodies, can be used as therapeutics to treat these 
diseases. Proteases constitute 5 to 10% of all pharmaceutical 
targets for small molecule drug discovery. To date, there 
have been six successful protease inhibitor drugs, including 
ACE inhibitors and HIV protease inhibitors [3], with inhibi-
tors for several additional proteases currently in clinical tri-
als. With over 560 proteases or protease homolog coding 
regions annotated from the human genome [1], this target 
class continues to be an important and active area for drug 
discovery. 
  Understanding protease function is critical to its applica-
tion as a biomarker for physiological processes or for the 
development of disease treatments. The substrate specificity 
of proteases confers preferential targeting of its substrate in 
the presence of other peptides and proteins. Therefore, a bet-
ter understanding of the binding to, and processing of, novel 
proteases with their natural substrates may help elucidate 
both their structure and function as well as suggest potential 
small molecule modulators [4]. Studying novel proteases 
using natural substrates can be technically difficult and 
therefore, many begin by first using short polypeptides as  
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substrates. Standard methods of determining protease sub-
strate specificity involve creating chemical combinatorial 
libraries of short polypeptides, typically tagged with fluoro-
phores, and quencher molecule if the protease has a P' re-
quirement [5-7]. This systematic approach provides a very 
rigorous and comprehensive method for determining sub-
strate specificity. However it requires expertise and equip-
ment for chemical synthesis, which are not readily available 
to most life science research laboratories. Fluorescent pep-
tide substrates can also be purchased from commercial ven-
dors but may be limited and costly. As an alternative to fluo-
rescent peptides, some investigators have created protein 
fusion libraries which contain the potential substrate se-
quences and then rank specificity based upon the percent of 
cleaved product as measured by gel densitometry [8]. But 
this approach, in addition to being laborious and time con-
suming, has limited assay dynamic range and sensitivity. 
  Once the optimal peptide sequence has been established, 
most researchers use fluorescent peptides synthesized in-
house or purchased from commercial sources, for their sub-
sequent protease characterization studies. While adequate for 
many applications, these fluorescence assays may have limi-
tations in sensitivity and dynamic range. Increasingly, inves-
tigators have turned to peptide conjugated aminoluciferin 
substrates. These bioluminescent substrates are significantly 
more sensitive and have wider dynamic ranges than analo-
gous fluorescent substrates, typically 100 times more sensi-
tive and 10-100 times wider dynamic range, in both bio-
chemical and cell-based assay formats [9]. Additionally 
when performing a library screen for small molecule modu-
lators, bioluminescent-based assays have been shown to be 
less hindered by non-specific compound interference than 
fluorescent-based assays [9-11]. 
  We have previously described a novel biosensor using a 
genetically modified firefly luciferase that allows the facile 
interrogation of protease function without chemical synthesis 
[12]. It uses a bioluminescent substrate generated through Protease Assay Using Engineered Luciferase  Current Chemical Genomics, 2008, Volume 2    17 
molecular cloning and transcription/translation coupled cell-
free expression. Thus protease substrates do not need to be 
purchased or chemically synthesized. The modified firefly 
luciferase is covalently joined at the native termini with a 
short peptide containing the protease recognition site which 
serves to restrict the luminescent reaction. Proteolytic cleav-
age of the peptide by the cognate protease activates the lu-
ciferase enzyme, typically over 100 fold. To express this 
mutant luciferase, new termini were inserted to create the 
circularly permuted form of firefly luciferase. The design 
strategy of this assay is shown in Fig. (1). Importantly, we 
have shown that this mutant luciferase protease assay retains 
the advantages of the bioluminescent format, which include 
increased sensitivity and wide dynamic range, while accom-
modating proteases with and without P' requirements [12]. 
  Here we further demonstrate the utility of this mutant 
luciferase for protease detection, interrogation of multiple 
protease substrates, small molecule modulator screening, and 
inhibitor potency determination. For our model system, we 
inserted the Tobacco Etch Virus (TEV) protease recognition 
sequence into the circularly permuted firefly luciferase gene. 
Using standard molecular cloning techniques we generated 
twenty substrates, differing at the P1' position, and examined 
the TEV protease recognition sequence specificity. One of 
these substrates was then used to screen the Library of 
Pharmacologically Active Compounds (LOPAC) for small 
molecule inhibitors of TEV protease and determine the po-
tency of a subset of these inhibitors.  
MATERIALS AND METHODOLOGY 
Primers were purchased from IDT. Sequencing was per-
formed by Agencourt Bioscience Corporation. Unless oth-
erwise specified, all other reagents are products of Promega 
Corporation (http://www.promega.com).  
Evaluation of Different Sites for Circular Permutation 
  Four different structurally tolerant firefly luciferase sites 
were evaluated for insertion of the new mutant luciferase 
termini. The TEV protease recognition sequence with linkers 
(GSS-ENLYFQS-SSG) was inserted into the luc2 gene, a 
synthetic firefly (Photinus pyralis) luciferase, circularly 
permuted (CP) at Thr235, Glu269, Leu309, and Pro359. The 
constructs encoded fusion proteins of the following type: 
Met-(Luc2 residues Y-544)- GSS-ENLYFQS-SSG -(Luc2 
residues 4-X)-Val (Table 1).  
Table 1.  Sites of Circular Permutation 
Circular Permutation (CP) site  X  Y 
235 233  235 
269 267  269 
309 307  309 
359 355  359 
 
  To synthesize these constructs, splice overlapping exten-
sion (SOE) PCR was performed [13]. Briefly, two general 
and two specific PCR primers for each construct were de-
signed to generate two PCR products containing the two 
halves of the mutant luciferase and TEV protease recognition 
sequence. The PCR primers were designed such that the 3' 
end of the first PCR product (the first half of the mutant lu-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic Representation of the CP234-Luc Assay.  
Firefly luciferase is a 61 kDa monomeric enzyme that catalyzes the oxidation of firefly luciferin in the presence of ATP and oxygen to emit 
yellow-green light. Upon binding of substrates, the structure of firefly luciferase undergoes conformational changes from open to closed 
forms. We created a circularly permuted luciferase by covalently joining the native N and C termini of firefly luciferase through the cloning 
in of a short polypeptide linker containing a protease recognition sequence. This results in restricting the movement between the two domains 
and locking the enzyme in the less active open form. Protease cleavage releases this constriction thereby restoring higher activity. A. To ex-
press this mutant luciferase, new N and C termini were inserted at amino acids 234 and 233, respectively. B. Insertion of the polypeptide 
linker greatly reduces luciferase activity. Proteolytic cleavage by the cognate protease (scissors) activates the mutant luciferase enzyme re-
sulting in a luminescent signal in the presence of the luciferin substrate (yellow circle). 
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ciferase and TEV protease recognition sequence) overlapped 
with the 5' end of the second PCR product (the second half 
of the mutant luciferase and TEV protease recognition se-
quence). A second round of (primerless) PCR splices the two 
PCR fragments together. This is followed by a third and final 
round of PCR using the two external primers which results in 
a single full length product. The final PCR product was then 
gel purified and ligated into the Flexi vector pF9A. One 
positive clone each was sequence confirmed (Agencourt). 
These constructs were kindly supplied by B.F. Binkowski. 
The resultant clones were then transferred into the Flexi vec-
tor pF3K for expression in cell-free translation reactions. 
Transfer of the coding regions into Flexi vectors pF9A and 
pF3K were performed according to the manufacturer’s direc-
tions.  
  The two internal primers (2 and 3) were the same for all 
four constructs. Primer 2 was 5'-TTGGCACCGGAGCT 
CGATTGGAAGTACAGGTTCTCGCTCGAGCCCTTCTT 
GGCCTTAATGAGAATCTCGC -3' and primer 3 was 5'-
AAGAAGGGCTCGAGCGAGAACCTGTACTTCCAATC 
GAGCTCCGGTGCCAAAAACATTAAGAAGGGCC -3'. 
The two unique PCR primers were as follows. For CP235, 
primer 1 was 5'- GCGATCGCCATGACCGCTATCCTCAG 
CGTGGTG -3' and primer 4 was 5'- GTTTAAACTCAGGG 
GATGATCTGGTTGCCGAAG -3'. For CP269, primer 1 
was 5'- GCGATCGCCATGGAGGAGGAGCTATTCTTGC 
GCAG -3' and primer 4 was 5'- GTTTAAACTCAGCGGT 
ACATGAGCACGACCC -3'. For CP309, primer 1 was 5'- 
GCGATCGCCATGTTGCACGAGATCGCCAGCGG-3' 
and primer 4 was 5'- GTTTAAACTCAGCTTAGGTCGTA 
CTTGTCGATGAGAG-3'. For CP359, primer 1 was 5'- 
GCGATCGCCATGCCTGGCGCAGTAGGCAAGG-3' and 
primer 4 was 5'- GTTTAAACTCACCCTTCGGGGGTGAT 
CAGAATG-3'. 
  The first round of PCR reactions amplified the two 
halves of the mutant luciferase coding region in two inde-
pendent reactions. PCR 1 reaction components were: 0.5 L 
50 ng/L plasmid DNA template (containing the luc2 coding 
region); 5 L 10X buffer; 5 L 2 mM dNTPs; 2 L 25 mM 
MgSO4; 33.5 L dH2O; 1.5 L 10 pmol/L sense primer 
(primer 1 or 3); 1.5 L 10 pmol/L antisense primer (primer 
2 or 4); 1 L KOD Hot Start DNA Polymerase (Novagen). 
PCR 1 cycling parameters were: an initial denaturation step 
at 94°C for 2 minutes followed by 25 cycles of denaturation 
at 94°C for 30 seconds; annealing at 50°C for 30 seconds; 
extension at 68°C for 1 minute and a final extension of 68°C 
for 7 minutes. After the removal of the residual PCR primers 
using the Wizard SV Gel and PCR Clean-Up System, the 
second PCR reaction was performed. PCR 2 reaction com-
ponents were: 1 ng/bp each purified PCR templates from the 
first round of PCR reactions; 5 L 10X buffer; 5 L 2 mM 
dNTPs; 2 L 25 mM MgSO4; dH2O to 50 L total volume; 1 
L KOD Hot Start DNA polymerase. PCR 2 cycling pa-
rameters were: an initial denaturation step at 94°C for 2 min-
utes followed by 10 cycles of denaturation at 94°C for 30 
seconds; annealing at 55°C for 30 seconds; extension at 
68°C for 1 minute and a final extension of 68°C for 7 min-
utes. PCR 3 immediately followed the PCR 2 reactions with-
out template purification. The PCR 3 reaction components 
were: 1 L PCR 2 product; 5 L 10X buffer; 5 L 2 mM 
dNTPs; 2 L 25 mM MgSO4; 1.5 L 10 pmol/L outside 
primer 1; 1.5 L 10 pmol/L outside primer 4; 33 L dH2O; 
1 L KOD Hot Start DNA polymerase. The PCR 3 cycling 
parameters were identical to the PCR 1 cycling parameters.  
  pF3K plasmid DNA encoding the circularly permuted 
luciferase with the TEV protease recognition sequence cod-
ing region, pF3K-CP235, 269, 309, 359-Luc/ENLYFQS, were iso-
lated from E. coli using the PureYield Plasmid Midiprep kit 
and used as template in the TNT
® SP6 High-Yield Protein 
Expression System according to the manufacturer’s instruc-
tions. Briefly, 2 g of DNA (or water: “no DNA” lysate) was 
added to 30 L master mix lysate plus 2 L FluoroTect™ 
GreenLys in vitro Translation Labeling System for visualiza-
tion on SDS-PAGE gels and the total volume was brought to 
50 L with dH2O. The 50 L in vitro translation reactions 
were then incubated at 25°C for 2 hours. Fifteen L of the 
reaction was then mixed with 15 L of a 2X ProTEV prote-
ase buffer (100mM HEPES, 1mM EDTA, pH 7.0, plus fresh 
2 mM DTT) with 1 L of ProTEV protease (10U/L) or 
dH2O. The digest reactions were incubated at 30°C for 30 
minutes. Five L of the digest reactions were placed in a 
white, flat bottom 96-well luminometer plate, in triplicate, 
and luminescence was measured following injection of 100 
L of Luciferase Assay Reagent using a Glomax
® 96 mi-
croplate luminometer (3 second integration time). Five L of 
the digest reactions were also size-fractionated on a 4-12% 
NuPAGE
® SDS-PAGE gel (Invitrogen) in MES buffer and 
visualized on a fluorimager (ex. 488nm / em. 532nm, Ty-
phoon
® 9410, GE Healthcare Bio-Sciences). 
P1' Specificity 
  To examine the P1' specificity of the TEV protease rec-
ognition sequence, we first created a vector with unique re-
striction sites. Here the luc2 gene was circularly permuted at 
Asp234, where X=233 and Y=234. The pF3A-based Flexi 
vector carries the CP234-Luc coding region with two unique 
restriction sites, NheI and BglII, inserted at the native lu-
ciferase N and C termini to facilitate the cloning in of prote-
ase recognition sequences. These two restriction sites also 
code for flexible linkers Ala-Ser and Gly-Ser on the N and C 
end of the protease recognition sequence, respectively. The 
glycine amino acid was created by destroying the BglII re-
striction site during the ligation step. Next, twenty oligonu-
cleotide pairs were synthesized (IDT) which encoded for the 
polypeptide ENLYFQX, where X was all possible amino 
acids (Table 2). The oligonucleotides also contained the spe-
cific NheI and BglII 5' and 3' overhangs for direct ligation 
into the pF3A-CP234-Luc acceptor vector. The oligonucleo-
tide pairs were hybridized together and ligation reactions 
performed using 50 ng linearized pF3A-CP234-Luc vector 
and 10 nM hybridized oligonucleotides according to manu-
facturer’s protocol. One positive clone each was then se-
quence confirmed (Agencourt).  
CP234-Luc/ENLYFQX Protein Expression 
 The  CP234-Luc/ENLYFQX plasmid DNA were isolated 
from E. coli using the PureYield Plasmid Midiprep kit and 
used as template in the TNT
® SP6 High-Yield Protein Ex-
pression System according to the manufacturer’s instruc-
tions. Briefly, 2 g of DNA (or water: “no DNA” lysate) was 
added to 30 L master mix lysate plus 2 L FluoroTect™ 
GreenLys in vitro Translation Labeling System for visualiza-
tion on SDS-PAGE gels and the total volume was brought to 
50 L with dH2O. The 50 L in vitro translation reactions Protease Assay Using Engineered Luciferase  Current Chemical Genomics, 2008, Volume 2    19 
were then incubated at 25°C for 2 hours. Fifteen L of the 
reaction was then mixed with 15 L of a 2X ProTEV prote-
ase buffer (100mM HEPES, 1mM EDTA, pH 7.0, plus fresh 
2 mM DTT) with 1 L of ProTEV protease (10U/L) or 
dH2O. The digest reactions were incubated at 30°C for 30 
minutes. Luminescence was measured from 5 L of each 
digest reaction, in triplicate, following injection of 100 L of 
Luciferase Assay Reagent using a MicroLumatPlus Mi-
croplate Luminometer LB96V (5 second integration time, 
EG&G Berthold). Five L of the digest reactions were also 
size-fractionated on a 4-20% Criterion Tris-HCl SDS-PAGE 
gel (BioRad) in TGS buffer and visualized on a fluorimager 
(ex. 488nm / em. 532nm, Typhoon
® 9410, GE Healthcare 
Bio-Sciences). 
TEV Protease Limit of Detection and Linear Range using 
the CP234-Luc/ENLYFQS Assay 
  To determine the sensitivity and linearity of the CP234-
Luc/ENLYFQS assay, titrating amounts of TEV protease 
were mixed with the CP234-Luc/ENLYFQS substrate (ex-
pressed using the TNT
® SP6 High-Yield Protein Expression 
System) and luminescence was measured. Two g CP234-
Luc/ENLYFQS plasmid DNA (or water: “no DNA” lysate) 
was used as template and expressed as above. After expres-
sion, 15 L of the lysate was mixed with 15 L of a 2X Pro-
TEV protease buffer plus titrating amounts of ProTEV pro-
tease (0 U to 3.16U). The digest reactions were incubated at 
30°C for 30 minutes. Five L of the digest reactions were 
placed in a white, flat bottom 96-well luminometer plate, in 
quadruplicate, and 100 L of 1:1 diluted Bright-Glo™ Lu-
ciferase Assay Reagent in dH2O was added to each well. 
After incubation at room temperature for 5 minutes, lumi-
nescence was measured using a Glomax
® 96 microplate lu-
minometer (1 second integration time).  
  The signal to noise (S/N) was calculated from the 
luminescent values. S/N is defined as: 
S/N =   mean signal – mean background 
    standard deviation of background 
For this assay,  
mean signal = mean signal RLU – the mean no-DNA RLU, 
at the various TEV concentrations  
mean background = mean signal RLU – the mean no-DNA 
RLU, when no TEV enzyme was added 
standard deviation of background = standard deviation of the 
signal RLU replicates, when no TEV enzyme was added 
LOPAC
1280 Library Screen 
  The Library of Pharmacologically Active Compounds 
(LOPAC
1280; Sigma-Aldrich) was screened for TEV protease 
Table 2.  Oligonucleotide Pairs for the Interrogation of TEV Protease Recognition Sequence P1' Position (ENLYFQX) 
X =  Forward primer sequence (5' - 3')  Reverse primer sequence (5' - 3') 
A CTAGCGAGAACCTGTACTTCCAGGCCG  GATCCGGCCTGGAAGTACAGGTTCTCG 
C CTAGCGAGAACCTGTACTTCCAGTGCG  GATCCGCACTGGAAGTACAGGTTCTCG 
D CTAGCGAGAACCTGTACTTCCAGGACG  GATCCGTCCTGGAAGTACAGGTTCTCG 
E CTAGCGAGAACCTGTACTTCCAGGAGG  GATCCCTCCTGGAAGTACAGGTTCTCG 
F CTAGCGAGAACCTGTACTTCCAGTTCG  GATCCGAACTGGAAGTACAGGTTCTCG 
G CTAGCGAGAACCTGTACTTCCAGGGCG  GATCCGCCCTGGAAGTACAGGTTCTCG 
H CTAGCGAGAACCTGTACTTCCAGCACG  GATCCGTGCTGGAAGTACAGGTTCTCG 
I CTAGCGAGAACCTGTACTTCCAGATCG  GATCCGATCTGGAAGTACAGGTTCTCG 
K CTAGCGAGAACCTGTACTTCCAGAAGG  GATCCCTTCTGGAAGTACAGGTTCTCG 
L CTAGCGAGAACCTGTACTTCCAGCTGG  GATCCCAGCTGGAAGTACAGGTTCTCG 
M CTAGCGAGAACCTGTACTTCCAGATGG  GATCCCATCTGGAAGTACAGGTTCTCG 
N CTAGCGAGAACCTGTACTTCCAGAACG  GATCCGTTCTGGAAGTACAGGTTCTCG 
P CTAGCGAGAACCTGTACTTCCAGCCAG  GATCCTGGCTGGAAGTACAGGTTCTCG 
Q CTAGCGAGAACCTGTACTTCCAGCAGG  GATCCCTGCTGGAAGTACAGGTTCTCG 
R CTAGCGAGAACCTGTACTTCCAGCGCG  GATCCGCGCTGGAAGTACAGGTTCTCG 
S CTAGCGAGAACCTGTACTTCCAGAGCG  GATCCGCTCTGGAAGTACAGGTTCTCG 
T CTAGCGAGAACCTGTACTTCCAGACCG  GATCCGGTCTGGAAGTACAGGTTCTCG 
V CTAGCGAGAACCTGTACTTCCAGGTGG  GATCCCACCTGGAAGTACAGGTTCTCG 
W CTAGCGAGAACCTGTACTTCCAGTGGG  GATCCCCACTGGAAGTACAGGTTCTCG 
Y CTAGCGAGAACCTGTACTTCCAGTACG  GATCCGTACTGGAAGTACAGGTTCTCG 20    Current Chemical Genomics, 2008, Volume 2  Wigdal et al. 
inhibitors in 384-well plates. CP234-Luc/ENLYFQC and a 
CP234-Luc/42 amino acid Gly/Ser rich peptide (CP234-
Luc/42AA; previously described [12]) plasmid DNA were 
isolated from E. coli using the PureYield Plasmid Maxiprep 
kit. Six mL translation reactions for each were made using 
the TNT
® SP6 High-Yield Protein Expression System. The 
reactions were gently rotated (~60 rpm) in a 50 mL conical 
tube for 2 hours at 25°C. The LOPAC
1280 library of com-
pounds was placed into two sets of four white, flat bottomed 
384-well plates with each well containing 5 μL of compound 
at a concentration of 0.5 mM in DMSO. Columns 1, 2, 23, 
and 24 on each plate were used for solvent and enzyme con-
trol samples.  
  The library screens were performed using a Freedom 
EVO automation platform with a TeMo multi-channel pipet-
ting system (Tecan). The translations were diluted into 
buffer as follows. For the CP234-Luc/ENLYFQC translation, 
5.83 mL was added to 3.0 mL of 20X ProTEV protease 
buffer, 60 μL 1 M DTT and dH2O to a final volume of 35 
mL. For the CP234-Luc/42AA, 5.83 mL was added to 3.0 mL 
20X ProTEV protease buffer, 60 μL 1M DTT, 11.7 mL 10 
mM HEPES, pH 7.5, and dH2O to 46.7 mL. To assay the 
effect of the compounds on the CP234-Luc/42AA, 20 μL of 
the CP234-Luc/42AA mixture was added to all wells in one 
set of four plates. To the second set of four plates, 5 μL Pro-
TEV protease diluted to 0.5 U/μL in 10 mM HEPES, pH 7.5 
was added, except for the no enzyme control lanes which 
received only dilution buffer. The same set of plates then 
received 15 μL of the CP234-Luc/ENLYFQC mix. The plates 
were spun down after each addition and were allowed to 
incubate 15 minutes at room temperature after the final addi-
tion. After this incubation, 25 μL Bright-Glo™ Luciferase 
Assay Reagent was added to each well of all plates. After 
incubation at room temperature for 5 minutes, the plates 
were read using a GENios Pro detection instrument (200 ms 
integration time; Tecan). 
CP234-Luc/ENLYFQC Verification Assays  
 CP234-Luc/ENLYFQC verification assays were per-
formed as follows. Fifteen L TNT
® SP6 High-Yield Protein 
Expression System lysate expressing CP234-Luc/ENLYFQC 
or CP234-Luc/42AA was mixed with 5 L compound or ve-
hicle, 7.5 U ProTEV protease and 1X ProTEV protease 
buffer (final concentration) in a total volume of 30 L. The 
reactions were incubated at room temperature for 15 minutes 
and then stopped by adding 5 L of the reaction, in triplicate, 
to 100 L of a 1:1 dilution of Bright-Glo™ Luciferase Assay 
Reagent in dH2O. After 5 minutes at room temperature, lu-
minescence was measured using a GloMax
® 96 microplate 
luminometer (1 second integration time). TEV protease 
cleavage of CP234-Luc/ENLYFQC was normalized to CP234-
Luc/42AA such that the ratio of CP234-Luc/ENLYFQC lumi-
nescence to CP234-Luc/42AA luminescence at no compound 
was 1.0. These normalized ratios were plotted against the 
logarithm of compound concentration and fit to a sigmoidal 
dose-response curve using GraphPad Prism 4 to estimate 
IC50 values. 
Protein Fusion Cleavage Assays  
  A fusion protein of glutathione-S-transferase and maltose 
binding protein (GST-MBP) with the TEV protease recogni-
tion sequence and linkers (SGGGGG-ENLYFQA-IA) in-
between the GST and MBP was created by cloning the MBP 
gene into the pFN2K Flexi vector. This vector carries the 
GST coding region upstream of the two unique restriction 
sites into which the MBP was cloned. The 5' unique restric-
tion site, SgfI, codes for amino acids AIA, thus the first 
alanine becomes the P1' position for the TEV protease recog-
nition sequence. This fusion protein was then expressed in 
KRX cells. The protein was purified using glutathione se-
pharose (GE Healthcare) as per the manufacturer’s direc-
tions. Protein concentration was estimated using Coomassie 
Plus Protein Assay Reagent (Pierce), using BSA as the stan-
dard. 
 One  hundred  L reactions containing 35.5 g GST-MBP, 
1X ProTEV protease buffer, 1 mM DTT, titrating amounts 
of compound (or vehicle), and 10 U ProTEV protease were 
incubated at 30°C for 15 minutes. Reactions were stopped 
with the addition of 4X SDS sample buffer plus 200 mM 
DTT (final concentration was 1X SDS sample buffer plus 50 
mM DTT). Samples were size fractionated on 4-20% Crite-
rion Tris-HCl SDS-PAGE gels (BioRad) in TGS buffer. Gels 
were then stained with SimplyBlue SafeStain (Invitrogen) 
and destained overnight in water at room temperature. Gels 
were then scanned on a fluorimager (Typhoon
® 9410, GE 
Healthcare Bio-Sciences) at 450V using no excitation or 
emission filters. Densitometry analysis (ImageQuant, GE 
Healthcare) was performed to determine percent cleavage of 
each sample. Each compound concentration was run in du-
plicate. Compounds were diluted in DMSO, except for NF-
023 hydrate, which was diluted in dH2O. The above protein 
fusion cleavage assay conditions were designed such that the 
percent cleavage of the no compound control was 70-80%. 
Starting below 95-100% cleavage ensures the assay quantita-
tively measures inhibition. Percent cleavage data was plotted 
against the logarithm of compound concentration and fit to a 
sigmoidal dose-response curve using GraphPad Prism 4 to 
estimate the IC50 values. 
RESULTS 
Establishment of an Optimal CP Site for the Engineered 
Luciferase TEV Protease Assay  
  Four circularly permuted luciferases containing the TEV 
protease site were created: CP235, 269, 309, 359 -Luc/ENLYFQS. 
For each of these constructs, the site of circular permutation 
was chosen in a solvent exposed surface loop bounded by 
secondary structures such as a beta sheet or alpha helix using 
PDB file 1LCI (http://www.rcsb.org/pdb/home/home.do).  
  All four mutant luciferases were activated upon TEV 
protease digest as determined by both an increase in lumi-
nescence as well as the appearance on SDS-PAGE gel of the 
expected sized lower molecular weight CP-Luc protein 
fragments (Fig. 2). The four proteins were digested to a simi-
lar degree resulting in their predicted fragments: CP235-Luc, 
34 and 26 kDa; CP269-Luc, 30.5 and 29.5 kDa; CP309-Luc, 
25.5 and 34.5 kDa; and CP359-Luc, 20 and 40 kDa (Fig. 2B). 
The CP235-Luc/ENLYFQS protein generated significantly 
more light output, both before and after cleavage, than the 
other three proteins. In addition, protease digest of the CP235-
Luc/ENLYFQS protein resulted in the largest fold activation 
(550 fold activation; Fig. 2A). In the case of the CP309-
Luc/ENLYFQS and CP359-Luc/ENLYFQS, the undigested 
luminescent values were less than three standard deviations Protease Assay Using Engineered Luciferase  Current Chemical Genomics, 2008, Volume 2    21 
above the “no DNA” lysate values. This indicates that their 
basal luminescent values were within the background 
“noise” of the GloMax
® 96 microplate luminometer and 
therefore fold activations could not be calculated. Based on 
these results, we chose to use a mutant luciferase circularly 
permuted near Thr235, at Asp234, for all our subsequent 
studies. 
Evaluation of TEV Protease Substrate Specificity 
  To enable both a comprehensive and easy method for 
interrogating protease specificity, we created a vector which 
carries the CP234 -Luc coding region with two unique restric-
tion sites inserted at the native luciferase N and C termini to 
facilitate the cloning in of protease recognition sequences. 
Using this vector, we generated twenty bioluminescent pro-
tease substrates: CP234-Luc/ENLYFQX proteins with all pos-
sible amino acids at the P1' position, to assess the utility this 
assay for examining protease substrate specificity. Nineteen 
of the twenty were activated to various degrees upon TEV 
protease digest as determined by both an increase in lumi-
nescence (Fig. 3) as well as the appearance of the smaller 34 
kDa and 26 kDa CP234-Luc protein fragments (data not 
shown). The CP234-Luc/ENLYFQP protein was not activated 
by or digested by TEV protease. The fold activations of the 
proteins after protease digestion ranged from none (P1' = 
proline) to 420 (P1' = serine). Gel analysis of the digested 
luciferase fragment showed qualitatively similar results, al-
though precise quantitation is difficult (data not shown). 
These results suggest that most amino acids are tolerated at 
the P1' position, with the exception of proline. This is consis-
tent with previous reports [8]. 
Determination of TEV Protease Substrate Detection 
Limit and Linear Range  
  To determine the sensitivity and linear range of the 
CP234-Luc/ENLYFQS assay, a TEV enzyme titration was 
performed. The luminescence from the CP234-Luc/ENL-
YFQS assay was dependent on the TEV enzyme concentra-
tion. The signal to noise (S/N) was calculated from the lumi-
nescent values and is defined as the mean signal – mean 
background divided by the standard deviation of the back-
ground (Fig. 4). The limit of detection was defined as the 
amount of TEV protease detected at a S/N of 3 (i.e., 3 stan-
dard deviations higher than the background). Thus the limit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Evaluation of Sites for Circular Permutation. 
A. Cleavage dependent activation of CP-Luc/ENLYFQS fusion protein. Cell-free translation reactions were diluted 1:1 in 2X TEV protease 
buffer, incubated at 30ºC for 30 minutes ± 10 U TEV protease and luminescence was measured from 5 μL aliquots. Data are the mean val-
ues, N = 3. Error bars are the standard deviation of the mean. B. Five μL of the protease digest reaction was size-fractionated on NuPAGE
® 
gels and FluoroTect
TM labeled proteins were visualized on a fluoroimager. TEV protease digestion resulted in the expected sized fragments. 
Note, the digestions were not complete, and therefore, residual undigested 60 kDa protein remains in all of the “+” lanes. No expressed pro-
tein is visible in the no DNA lanes. 
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of detection was 0.163 mU TEV protease per 100 μL Bright 
Glo
TM Luciferase Assay sample. The linear range of the as-
say was  1,000 fold (0.163 to 167 mU (the highest concen-
tration tested in this experiment) of TEV protease per 100 μL 
Bright Glo
TM Luciferase Assay sample). 
Screening of TEV Protease Inhibitors 
  TEV protease is widely used as a tool to cleave an affin-
ity tag from the protein of interest after protein purification. 
Therefore, it is desirable to have an inhibitor that can “turn 
off” TEV protease after fusion protein cleavage, but does not 
affect subsequent processing steps. Our initial attempts using 
known cysteine inhibitors either failed to inhibit TEV prote-
ase or affected downstream applications. To find a suitable 
inhibitor, we screened the LOPAC
1280 library compounds in 
384-well format at 100 μM using the CP234-Luc/ENLYFQC 
protease assay to identify potential small-molecule inhibi-
tors. 
  To control for non-specific CP234-Luc affecters, we used 
a previously described CP234-Luc protein containing a 42 
amino acid glycine/serine rich sequence [12]. This 42 amino 
acid glycine/serine rich sequence is not recognized by native 
proteases in the TnT
® SP6 High-Yield lysate or by the TEV 
protease (data not shown). Because of the long length of this 
polypeptide, the basal luminescence of the CP234-Luc/42AA 
protein was approximately 10 times greater than the lumi-
nescence of the CP234-Luc/ENLYFQC protein after TEV 
protease digestion. The luminescence of the CP234-
Luc/42AA protein was determined by incubating the protein 
in the TEV assay conditions with DMSO solvent. The lumi-
nescence of the CP234-Luc/42AA protein was also measured 
in the presence of the LOPAC
1280 library. Therefore, non-
specific affecters were detected by a change in the CP234-
Luc/42AA protein luminescent signal from the DMSO sol-
vent control. Incubation with twenty-five LOPAC
1280 library 
compounds (out of 1280 compounds, 2%) resulted in a 
CP234-Luc/42AA luminescent signal outside three standard 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Evaluation of TEV Protease Recognition Sequence P1' Specificity. 
Cleavage dependent activation of CP234-Luc/ENLYFQX fusion proteins. Cell-free translation reactions were diluted 1:1 in 2X TEV protease 
buffer, incubated at 30ºC for 30 minutes ± 10 U TEV protease and luminescence was measured from 5 μL aliquots. The X-axis is the amino 
acid at the P1' position (X) of the CP234-Luc/ENLYFQX fusion protein. The Y-axis is the fold activation of the CP234-Luc/ENLYFQX fusion 
proteins calculated by dividing the mean TEV digested values by the mean undigested values (no TEV digest), N = 3. Error bars are the stan-
dard deviation of the mean. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). TEV Protease Titration. 
TEV protease dose dependent activation of CP234-Luc/ENLYFQS protein. Cell-free translation reactions were diluted 1:1 in 2X TEV prote-
ase buffer, incubated at 30ºC for 30 minutes with titrating amounts of TEV protease and luminescence was measured from 5 μL aliquots in 
100 μL 1:1 diluted Bright Glo
TM Luciferase Assay reagent in dH2O; N = 4. Results are plotted as signal to noise (S/N). The limit of detection 
was defined as the amount of TEV protease giving a S/N ratio = 3 (dotted line). The R
2 value was 0.99.  
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deviations from the mean of the DMSO solvent control. Pre-
sumably these compounds either interfere with CP234-Luc 
activity or, as with highly colored compounds, they may be 
quenching the luminescent signal produced by the CP234-Luc 
[11].  
  Hits were defined as those compounds which inhibited 
TEV protease activity greater than 60%. We chose to only 
examine these compounds because our goal was to find a 
very potent inhibitor of TEV protease activity. Representa-
tive screen data from plate 1 is shown (Fig. 5). On plate 1 
there were three hits based on greater than 60% TEV prote-
ase inhibition: one was confirmed as an inhibitor, aurintri-
carboxylic acid (ATA; yellow triangle), one was not re-
tested (green triangle) and one also caused a reduction in 
CP234-Luc/42AA assay activity (blue triangle and gray/black 
square), suggesting that the compound is non-specifically 
affecting the luminescent reaction. One additional compound 
(gray/black square) caused an increase in CP234-Luc/42AA 
activity; however it did not appear to affect the CP234-
Luc/ENLYFQC assay activity. 
In total, twenty-one compounds inhibited greater than 60% 
of the TEV protease cleavage of CP234-Luc/ENLYFQC (out 
of 1280 compounds, 1.6%). Nine of the 21 compounds 
which inhibited greater than 60% of the TEV protease cleav-
age of CP234-Luc/ENLYFQC also resulted in a CP234-
Luc/42AA luminescent signal outside three standard devia-
tions from the mean of the DMSO solvent control and thus 
were excluded from further analysis. The remaining 12 com-
pounds were, therefore, potential TEV protease specific in-
hibitors (out of 1280 compounds, 0.9%).  
Five of the 12 compounds were re-tested using both the 
CP234-Luc/ENLYFQC assay and the protein fusion cleavage 
assay. We did not test all twelve compounds because of cost 
considerations. Instead, we chose to re-test a range of poten-
tial TEV protease inhibitors: three potent inhibitors (inhib-
ited >80% cleavage activity) and two moderate inhibitors 
(inhibited 60-70% cleavage activity). The five compounds 
were: aurintricarboxylic acid (ATA), 8,8'-[carbonylbis 
(imino-3,1-phenylenecarbonylimino)]bis(1,3,5-naphthalene-
trisulfonic acid) hexasodium salt (NF-023), 4-[3-(4-Acetyl-
3-hydroxy-2-propylphenoxy)propoxy]phenoxyacetic acid 
(L-165,041), SCH-202676 hydrobromide or N-(2,3-
diphenyl-1,2,4-thiadiazol-5-(2H)-ylidene)methanamine hy-
drobromide (SCH HBr), and 6-hydroxyl-DL-DOPA or 2,5-
dihydroxy-DL-tyrosine (L-DOPA). Three out of the five 
compounds showed dosage-dependent inhibition as shown in 
Fig. (6). For the CP234-Luc/ENLYFQC assay, NF-023 and 
ATA were tested from 0 – 0.2 mM and the other three com-
pounds were tested from 0 – 1 mM (Fig. 6A). For the protein 
fusion cleavage assay, compounds were tested from 0 – 0.1 
mM (Fig. 6B). Inhibitor potency ranking was determined by 
estimating the IC50 values (see Materials and Methodology; 
Table 3).  
Of the five compounds, SCH HBr and L-DOPA did not in-
hibit TEV protease cleavage in either assay re-test. The po-
tency ranking using the two assays was the same for two out 
of the three remaining compounds. In the case of ATA, an 
IC50 value could not be determined using the CP234-
Luc/ENLYFQC assay. This was most likely due to assay 
interference by the dark red color of ATA. ATA (by protein 
fusion cleavage assay) and NF-023 were determined to be 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Representative Data from Plate 1 of the LOPAC
1280 Library Screen. 
The LOPAC
1280 library was screened for TEV protease inhibitors using the CP234-Luc/ENLYFQC assay. Shown here are the data from plate 
1 (N = 320 compounds). There were three hits (    ,     ,     ) based on greater than 60% TEV protease inhibition, blue line (= 345,311 RLU). 
The CP234-Luc/42AA assay was also performed to detect potential non-specific affectors of the CP234-Luc assay and the results, which are 
overlaid on the graph in gray, indicate that two compounds non-specifically affected the assay. (   ) = CP234-Luc/42AA activity in DMSO;  
(    ,     ) = CP234-Luc/42AA activity with compound library; (    ) = CP234-Luc/ENLYFQC activity minus TEV enzyme in DMSO; (    ) = 
CP234-Luc/ENLYFQC activity plus TEV enzyme in DMSO, and (    ,     ,    ,    ) = CP234-Luc/ENLYFQC activity plus TEV protease with 
compound library. Controls are plotted as the mean of N = 64 (CP234-Luc/42AA in DMSO) or 32 (CP234-Luc/ENLYFQC ± TEV protease in 
DMSO). Error bars are the standard deviation of the mean. 
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potent inhibitors of TEV protease cleavage while L-165,041 
was a slightly weaker inhibitor.  
DISCUSSION 
  We have previously described the general applicability of 
a protease assay for substrate identification, with and without 
P' requirements, using a genetically engineered firefly lu-
ciferase biosensor, which is highly sensitive and has a wide 
dynamic range (Fig. 1) [12]. Furthermore, this assay does not 
require the purchase of, or chemical synthesis of, peptide 
substrates. In this report, we further demonstrate the utility 
of this assay for protease detection, substrate specificity 
analysis, small molecule inhibitor screening, and potency 
determination using TEV protease as a model system. 
  The TEV protease used in this study (ProTEV protease) 
is a 50kDa version of the NIa protease from TEV that has 
Table 3.  IC50 Determinations 
Compound IC50 by CP234-Luc/ENLYFQC IC50 by Protein Fusion Cleavage  
ATA N.D.  2.6  M 
NF-023 40  M 2.3  M 
L-165,041 146  M 90  M 
N.D. – not determined due to interference from the color of compound at high concentrations. ATA - aurintricarboxylic acid, NF-023 - 8,8'-[carbonylbis(imino-3,1-
phenylenecarbonylimino)]bis(1,3,5-naphthalene-trisulfonic acid) hexasodium salt, L-165,041 - 4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxyacetic acid. IC50 values 
were estimated by plotting activity against the logarithm of compound concentration and fitting the data to a sigmoidal dose response curve using GraphPad Prism 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Inhibitor Potency Titration Curves. 
Five compounds were re-tested at titrating concentrations. The five compounds were: aurintricarboxylic acid (ATA), 8,8'-
[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis(1,3,5-naphthalene-trisulfonic acid) hexasodium salt (NF-023), 4-[3-(4-Acetyl-3-
hydroxy-2-propylphenoxy)propoxy]phenoxyacetic acid (L-165,041), SCH-202676 hydrobromide or N-(2,3-diphenyl-1,2,4-thiadiazol-5-
(2H)-ylidene)methanamine hydrobromide (SCH HBr), and 6-hydroxyl-DL-DOPA or 2,5-dihydroxy-DL-tyrosine (L-DOPA). A. Using the 
CP234-Luc/ENLYFQC assay, NF-023 and ATA were tested from 0 – 0.2 mM and the other three compounds were tested from 0 – 1 mM. 
Data are the mean values, N = 3. Error bars are the standard deviation of the mean. B. Using the protein fusion cleavage assay, compounds 
were tested from 0 – 0.1 mM. Data are the average of N = 2. 
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been engineered to be more stable than native TEV protease 
[8, 14, 15]. TEV protease is a highly site-specific cysteine 
protease that recognizes the seven amino acid sequence 
EXXYXQ(G/S). This site is most commonly ENLYFQG, 
with cleavage occurring between glutamine and glycine or 
serine [16, 17]. However, the protease will recognize and 
cleave sequences with a variety of amino acids at the G/S (or 
P1') position [8]. The protease is used primarily to cleave 
affinity tags from fusion proteins after protein purification.  
  We have previously optimized the linker length and site 
of circular permutation for a non-lytic, live cell cAMP bio-
sensor which resulted in dramatic performance improve-
ments [12]. However, our previous protease assay optimiza-
tions were only focused on the length of the polypeptide in-
serted between the native N and C termini [12]. In this study, 
we examined the performance of the CP-Luc/ENLYFQS 
proteins circularly permuted at different sites (Fig. 2). All 
four proteins were similarly digested by the TEV protease 
(Fig. 2B). Therefore to determine the optimal circularly per-
muted site, we compared the luminescent values and fold 
activations of the four proteins (Fig. 2A). To calculate fold 
activation, it is necessary that the basal luminescent values 
are greater than three standard deviations above the “no 
DNA” control. CP309-Luc/ENLYFQS and CP359-
Luc/ENLYFQS basal luminescent values were within three 
standard deviations of the “no DNA control” and, since we 
could not calculate their fold activations, they were not cho-
sen. A comparison of the luminescent values and fold activa-
tions of the remaining two proteins, CP235 -Luc/ENLYFQS 
and CP269  -Luc/ENLYFQS, showed that the most optimal 
protein in terms of basal and activated luminescence as well 
as fold activation was the CP235  -Luc/ENLYFQS protein 
(Fig. 2A). We therefore used a mutant luciferase circularly 
permuted near Thr235, at Asp234, for all our subsequent 
studies (Figs. 3-6).  
  One of our main objectives for this protease assay was to 
facilitate the easy and rapid evaluation of multiple protease 
substrates. Although other methodologies exist, they can be 
prohibitive in terms of the cost to purchase the substrates or 
in the expertise required to synthesize the substrates. In the 
case of protein fusion cleavage assays, they are laborious to 
perform and are not well suited for high throughput screen-
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Fig. (7). Chemical Structures of Three TEV Inhibitor Compounds. 
Three compounds found in the LOPAC
1280 library screen as TEV inhibitors were confirmed using both the CP234-Luc/ENLYFQC assay and 
the protein fusion cleavage assay. Their chemical structures are: A. aurintricarboxylic acid (ATA), B. 8,8'-[carbonylbis(imino-3,1-
phenylenecarbonylimino)]bis(1,3,5-naphthalene-trisulfonic acid) hexasodium salt (NF-023), C. 4-[3-(4-Acetyl-3-hydroxy-2-
propylphenoxy)propoxy]phenoxyacetic acid (L-165,041).  26    Current Chemical Genomics, 2008, Volume 2  Wigdal et al. 
ing applications. We therefore devised a bioluminescent-
based CP234-Luc cloning method where substrates could be 
quickly and easily generated. Using this method, we gener-
ated 20 substrates and performed a TEV protease substrate 
specificity study. Our results are consistent with previous 
reports [8]. Furthermore, the dynamic range for the CP234 -
Luc/ENLYFQS P1' substrate was 420 fold (Fig. 3).  
  One limitation of the CP234 -Luc method is that rigorous 
enzymatic analyses are difficult to perform. Since the prote-
ase substrates are generated in a cell-free lysate, the exact 
amount of substrate is hard to determine. Consequently, ex-
act quantitation analysis is challenging. Other methodologies 
also have limitations quantitatively measuring protease activ-
ity. For example, it is important that the protein fusion cleav-
age assay conditions are engineered such that the substrate 
digestions are not allowed to reach 100% completion. If not, 
multiple substrates may appear to be equally preferred by the 
protease. This was demonstrated by the near complete intra-
cellular processing of multiple substrates by TEV protease in 
E. coli [8]. Another potential limitation of protein fusion 
cleavage assays is their dependence on gel conditions and the 
densitometer dynamic range (sample loading, scan settings, 
etc.).  
  Nevertheless, the results from our semi-quantitative 
analysis based on fold of activation (Fig. 3) are consistent 
with results using other methods in previous reports [8]. The 
relative ranking of ten amino acids at the P1' position be-
tween the CP234 -Luc/ENLYFQS assay and an in vitro proc-
essing (protein fusion cleavage) assay were similar with two 
exceptions: Asp and Gln. The relative ranking of those two 
amino acids at the P1' position was significantly higher using 
CP234 -Luc/ENLYFQS assay than the in vitro processing gel 
cleavage assay [8]. One possible explanation for this differ-
ence may be the context in which the protease recognition 
sequence is presented. Since the context is non-native in both 
assays, it is possible that the differences observed in the rela-
tive rankings are due to the ability of the protease to access 
its substrate.  
 The  CP234  -Luc/ENLYFQS assay, similar to what we 
have previously demonstrated using a caspase-3 substrate 
(CP234  -Luc/DEVDG) [12], has a wide dynamic range, 
1,000 fold, and is highly sensitive with a limit of detection 
of 0.163 mU TEV protease / sample (Fig. 4). Unfortunately, 
we cannot compare the sensitivity of the CP234  -
Luc/ENLYFQS assay with an analogous fluorescent assay 
because, to the best of our knowledge, such an assay is not 
commercially available. However, we can compare the CP234 
-Luc/DEVDG assay [12] with both analogous fluorescent 
assays as well as an analogous peptide conjugated aminolu-
ciferin protease substrate assay [9]. The comparison between 
the assays can be estimated after normalizing the two differ-
ent sources of caspase-3 protease (and assuming that the 
substrates used to determine specific activity are compara-
ble). We estimated that the sensitivity of the CP234  -
Luc/DEVDG assay was 10 to 100 fold more sensitive than 
the two analogous fluorescent substrates tested; Rho110 and 
AMC and ~10 fold less sensitive than the Z-DEVD-
aminoluciferin protease substrate assay. These results dem-
onstrate that the CP234 -Luc assay retains the high sensitivity 
and wide dynamic range afforded bioluminescence-based 
assays while enabling researchers to easily generate protease 
substrates of interest. 
  TEV protease is widely used as a tool to cleave a protein 
purification tag from the protein of interest. Therefore, we 
wanted to find an inhibitor which could “turn off” TEV pro-
tease after fusion protein cleavage, but did not affect subse-
quent processing steps. Initially, we tried several established 
inhibitors without success. For example, while 5 mM zinc 
effectively inhibited the protease, it also frequently precipi-
tated the proteins out of solution. Similarly, inactivation of 
TEV, a cysteine protease, with sulfhydryl modifying rea-
gents such as N-ethylmaleimide and iodoacetamide required 
concentrations at levels where other proteins in the solution 
were also modified. And finally, TEV protease proved resis-
tant to various known inhibitors of cysteine proteases, in-
cluding E-64 protease inhibitor, ALLN (N-acetyl-Leu-Leu-
NIe-CHO), and EST ((2S,3S)-trans-Epoxysuccinyl-L-
leucylamido-3-methylbutane Ethyl Ester) (data not shown). 
A peptide substrate analog with a chloromethylketone 
(CMK) in the P1' position was synthesized according to pre-
vious studies [18]. This hexapeptide peptide CMK inhibitor 
was able to inhibit TEV protease cleavage with an IC50 of 
~5.7 M as measured by the protein fusion cleavage assay. 
Complete inhibition was observed at 20 M after a 15 min-
ute pre-incubation with the protease before adding substrate 
(data not shown). However, the cost of the peptide-based 
inhibitor prohibited its practical use. 
  We screened the LOPAC
1280 library in 384-well format to 
find a small molecule inhibitor of TEV protease which 
would not affect subsequent processing steps. The library 
was screened at ten times the concentration of a typical 
screen (100 M versus 10 M) (Fig. 5). We chose to per-
form the screen at this high concentration to increase the 
probability of finding a very potent inhibitor of TEV prote-
ase. The high compound concentration likely resulted in a 
higher than expected number [9-11] of non-specific affecters 
of CP234-Luc/42AA luminescence, in part due to increased 
color quenching. Of the 25 compounds which non-
specifically affected the CP234-Luc/42AA luminescent sig-
nal, nine were visibly colored at 100 M, four have been 
previously shown to inhibit luciferase activity (M.A. 
O’Brien, personal communication); three appeared to in-
crease activity and the remaining nine compounds reduced 
activity. It would be interesting to determine the number of 
compounds which affect the CP234-Luc/42AA luminescent 
signal when screened at 10 M concentration.  
  Five of the 12 compound hits found in the primary screen 
were re-tested using the same CP234-Luc/ENLYFQC assay as 
well as a protein fusion cleavage assay. Protein fusion cleav-
age is the most commonly used assay to assess inhibition of 
TEV protease activity. The results from the two assays were 
the same in terms of confirming the three hits as well as the 
relative ranking of two of the three hits (Fig. 6; Table 3). The 
estimated IC50 for L-165,041 was similar (within 10 fold) 
between the two assays, but the estimated IC50 for NF-023 
was significantly different between the two assays. Although 
the reason for this difference is not understood, it is well 
known that different assays and conditions can result in dif-
ferent IC50 values. It is also worth noting that the P1' position 
of the TEV protease recognition sequence was not the same 
between the CP234-Luc/ENLYFQC and protein fusion cleav-
age assays, cysteine versus alanine, respectively. The ex-
periments for which the TEV protease inhibitor was intended 
required that the P1' amino acid be a cysteine. And since all Protease Assay Using Engineered Luciferase  Current Chemical Genomics, 2008, Volume 2    27 
bioluminescent substrates were readily available, we were 
able to choose that substrate for the screening study. But for 
the protein fusion cleavage assay, we did not have the option 
of choosing the P1' amino acid since alanine was pre-
engineered into the pFN2K parent vector. Fortunately in this 
case, based on the P1' position study (Fig. 3), we do not be-
lieve that the variations observed in the NF-023 IC50 values 
were a result of this difference. In other applications, how-
ever, the ability to precisely choose the exact protease sub-
strate may be critical.  
  The three confirmed TEV protease inhibitors were: aurin-
tricarboxylic acid (ATA), 8,8'-[carbonylbis(imino-3,1-
phenylenecarbonylimino)]bis(1,3,5-naphthalene-trisulfonic 
acid) hexasodium salt (NF-023), and 4-[3-(4-Acetyl-3-
hydroxy-2-propylphenoxy)propoxy]phenoxyacetic acid (L-
165,041). The chemical structures of the three compounds 
are shown in Fig. (7). ATA and NF-023 were strong TEV 
protease inhibitors while L-165,041 was a moderate inhibi-
tor. Although ATA is listed as a DNA topoisomerase II in-
hibitor in the Sigma LOPAC library database, it has also 
been shown to inhibit cysteine proteases such as calpain [19] 
and caspases 3, 6, 7, and 9 [20]. Therefore, our results show-
ing an inhibitory effect of ATA on the TEV cysteine prote-
ase are consistent with previous reports. NF-023, listed as a 
potent, selective P2X1 receptor antagonist in the Sigma LO-
PAC library database, is an analog of suramin, a hexasul-
fonated naphthylurea. Suramin has many, widely diverse 
uses such as to treat trypanosomiasis and onchocerciasis 
[21], as an anti-tumor drug [22-25], Malaria parasite Plamo-
dium falciparum erythrocyte invasion inhibitor [26], HIV-1 
reverse transcriptase inhibitor [27], and inhibitor of three 
neutrophil serine proteinases: neutrophil elastase, cathepsin 
G and proteinase 3 [28]. Interestingly, TEV protease is a 
serine-like cysteine protease. Thus it is possible that NF-
023’s inhibitory mechanism of action on TEV protease may 
be the same as suramin’s on the neutrophil serine protein-
ases. Further supporting this idea is the fact that two (out of 
12) additional hits found in the primary LOPAC screen were 
suramin and NF-449, another suramin analog. This suggests 
that a structure-activity relationship exists between suramin 
and related compounds and their TEV protease inhibitory 
properties. Finally, L-165,041 is a peroxisome proliferator-
activated receptor beta agonist. A search of the literature 
failed to yield any previous reports which would help ex-
plain this compound’s TEV protease inhibitory effects.  
 The  LOPAC
1280 library screen for TEV protease inhibi-
tors demonstrates that the CP234-Luc protease assay can be 
used to screen for small molecule modulators in a high 
throughput 384-well format. More studies will be needed to 
fully validate its utility for high throughput screening, for 
example, improving assay quality (i.e., Z’ and Z values cur-
rently around 0.4-0.5) on a larger and more diverse com-
pound library. Nevertheless, we were able to identify several 
novel TEV protease inhibitors. The use of these inhibitors to 
“turn off” TEV protease for applications in protein purifica-
tion is being explored. 
CONCLUSION 
  Proteases play a critical role in almost every aspect of 
biology. Therefore a better understanding of their often times 
complex functions and regulation, is vital to disease preven-
tion and treatment. One of the first steps when investigating 
novel proteases are to establish its substrate specificity and a 
robust assay. Here we have demonstrated the utility of a ge-
netically engineered luciferase protease assay which allows 
for the rapid and sensitive evaluation of multiple substrates 
without the need for chemically synthesize peptide sub-
strates, made in-house or purchased. For many, this will en-
able a more comprehensive study of novel proteases with the 
added increase in sensitivity and dynamic range afforded by 
the bioluminescent-based format. Once an optimal substrate 
sequence has been determined, that substrate can be directly 
used for applications such as protease detection, high 
throughput screening for protease modulators, and their fur-
ther characterizations.  
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